We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AWIQLI (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
AWIQLI
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
insulin icodec
Registration type
NCE/NBE
Indication
Treatment of Type 2 Diabetes in adults.
Treatment of Type 1 Diabetes in adults, in conjunction with a bolus insulin, where daily basal insulin injections are not suitable.